crme and mrk seems like a huge risk given that astellas hasn't even responded to the approvable indicating that there are serious issues with the inhaled version. I would imagine that MRK has done its due diligence and concluded that everything was tip top but then why the lengthy delay for the response?
Also if astellas was going to submit soon crme would have waited a little while longer to increase their leverage it seems to me.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.